Eurofins debuts combined tests for COVID-19, flu, RSV

LabPulse.com staff writers
Nov 17, 2020
2020 06 29 16 41 7549 Pathogenic Bacteria Viruses 400

Eurofins Viracor has launched several combined tests that detect SARS-CoV-2 infection, as well as influenza A and B and respiratory syncytial virus (RSV).

The combined SARS-CoV-2 plus flu A/B and RSV tests aim for the qualitative detection of SARS-CoV-2 and the quantitative detection of influenza A, influenza B, and RSV. The combined COVID-19 and flu test now can be ordered as individual tests.

The combined COVID-19, flu, and RSV test is expected to launch on December 7.

Latest in Influenza
Needle Shot Vaccine Teenager Social
NIH starts early-phase trial of second-generation universal flu vaccine candidate
September 20, 2023
Vaccine Injection Woman Social
Moderna’s mRNA flu shot yields promising results in phase III trial
September 15, 2023
Influenza Virus Social
COVID-19 still associated with higher death risk than flu
April 11, 2023
Fda Button Social
FDA grants 510(k) clearance to DiaSorin for COVID-19 and flu A/B assay
March 20, 2023
Related Stories
Fda Button Social
Emergency Use Authorization
Visby Medical receives FDA Emergency Use Authorization for respiratory test in CLIA-waived settings
Covid Test Preschool Social
COVID-19
Sameday Health launches swab test in Los Angeles for COVID-19, flu, RSV
Women Laboratory Social
Trends and Finance
Eurofins Viracor opens lab to support growth in biopharma, transplant diagnostic testing
2021 01 11 17 03 4617 Covid Diagnostic Test Kit 400
Molecular Diagnostics
Eurofins lands $30M COVID diagnostic testing contract
More in Influenza
NIH starts early-phase trial of second-generation universal flu vaccine candidate
The U.S. National Institutes of Health (NIH) has begun an early-phase clinical trial of its second-generation universal flu vaccine candidate.
September 20, 2023
Needle Shot Vaccine Teenager Social
Moderna’s mRNA flu shot yields promising results in phase III trial
Moderna announced that its mRNA flu shot that is in development has met its primary endpoints in a phase III trial, generating a stronger immune response than a commercially available flu vaccine.
September 15, 2023
Vaccine Injection Woman Social
COVID-19 still associated with higher death risk than flu
VA hospital patients with COVID-19 had a higher risk of death than seasonal influenza patients from fall 2022 to winter 2023.
April 11, 2023
Influenza Virus Social
FDA grants 510(k) clearance to DiaSorin for COVID-19 and flu A/B assay
The test detects and differentiates influenza A, influenza B, and SARS-CoV-2 viruses to help ensure physicians can recommend the most appropriate treatment for each patient.
March 20, 2023
Fda Button Social
Cepheid says its influenza assays mitigate impact of mutational drift seen in some tests
Two mutations in the matrix genes of the human influenza A virus have been reported to cause matrix gene target failure for several commercial diagnostic tests.
December 8, 2022
Flu Season Ahead Social
Reagent supplier launches antigens for Southern Hemisphere's 2023 flu season
The hemagglutinin and neuraminidase antigens were developed in response to flu vaccine formulations the World Health Organization selected for development in the Southern Hemisphere.
November 21, 2022
Flu Season Ahead Social
Virax introduces rapid test kit for RSV, influenza A/B, COVID-19
Virax Biolabs announced the distribution of a rapid antigen test kit capable of detecting when individuals have been infected with RSV, Influenza A/B, or COVID-19.
November 3, 2022
Respiratory Syncytial Virus Cdc Social
University of Illinois spinout Shield T3 launches saliva-based PCR test for COVID, flu, RSV
Shield T3, a spinout of the University of Illinois, will offer a triple-virus PCR test kit, in anticipation of increased cases of COVID-19, flu, and RSV this winter.
October 25, 2022
Covid Diagnostic Test Kit
Walgreens Flu Index shows 2022-2023 season exhibiting tenfold increase over last year
The Walgreens Flu Index indicates that flu activity this year is more than 10 times higher than in the previous year and has doubled over the past two weeks.
October 24, 2022
Influenza Virus Cdc
DiaSorin developing point-of-care molecular test for SARS-CoV-2, influenza under BARDA contract
DiaSorin will develop, verify, and clinically validate a point-of-care instrument and an initial combination test for SARS-CoV-2 and influenza A and B.
October 7, 2022
Influenza Virus
Siemens releases tests for seasonal respiratory pathogens
The CE-marked FTD SARS-CoV-2/FluA/FluB/HRSV PCR assay is available to laboratories, while the Clinitest Rapid COVID-19 + Influenza Antigen Test is used at the point of care.
September 14, 2022
2022 02 04 20 07 5010 Siemens Rsna 2021 400
MagBio Genomics secures 510(k), CE Mark approval
A guanidine-free molecular transport medium, the MagXtract Collection Tube eliminates the risk of accidentally creating cyanide gas during cleaning, directly lyses cells during transport, inactivates pathogens, and maintains ambient temperature stability of RNA samples for up to eight days, thus eliminating the need for cold storage and shipping, the firm said.
September 11, 2022
2019 02 13 19 24 5396 Fda Logo V2 400
Page 1 of 7
Next Page